AEterna Zentaris (AEZS) to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
Down)
AEterna Zentaris Inc. (NASDAQ: AEZS) reported that patient follow-up in the open-label safety study (study 041) of its Phase 3 program in benign prostatic hyperplasia (BPH) with its lead endocrinology compound, cetrorelix pamoate, is scheduled to be completed at the end of this week. Therefore, data analysis and reporting will be brought forward from the scheduled fourth quarter into the third quarter of 2009, and will follow the disclosure of results from the first double-blind placebo controlled efficacy study (study 033). BPH is a benign enlargement of the prostate, affecting more than 20 million men in the U.S. alone.
Subscribe to EasyStockAlerts.com & Get real-time e-mail alerts when news hits your stocks!
Subscribe to EasyStockAlerts.com & Get real-time e-mail alerts when news hits your stocks!
You May Also Be Interested In
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- Chelsea Therapeutics (CHTP) Completes End-of-Review Meeting with FDA Over Northera NDA
- Medicis (MRX) Gets Verbal Notice of Allowance for ZYCLARA Patent on Actinic Keratosis
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
